Paragonix Technologies Launches New OPTION On-Demand Preservation Services Network

Paragonix Technologies announces the launch of its new OPTION On-Demand Preservation Services Network in the United States. OPTION is an around-the-clock rapid deployment service designed to better serve the transplant community and improve efficiencies in donor organ procurement and recovery.

The company reports the first phase of the OPTION program has launched, including the establishment of a nationwide forward deployment of distributed inventory at responsive depots to ensure transplant surgeons have access to advanced hypothermic preservation technologies.

Due to increased product demands, and the challenging logistics associated with recovering, preserving and transporting donor organs, regularly in only a few hours and often in the middle of the night, Paragonix Technologies is launching this just-in-time service to ensure 24/7 availability of Paragonix organ preservation products.

In addition, with a rise in “local procurement,” an increasingly common situation where a transplant team local to the donor recovers the organ(s) and sends them to the recipient hospital transplant team, the need has increased for distributed inventory and a more rapidly deployed product. A recent recovery in Alaska required the securing of a locally inventoried Paragonix organ preservation device in under a few hours, to support the transport of a donor organ to the east coast. By increasing access to regionally available inventory, Paragonix will support logistically challenging procurements and improve the efficiency of the organ donation system.

“We are proud to offer the OPTION in collaboration with top logistics providers across the country,” says Garrett Riddle, VP Manufacturing at Paragonix Technologies. “Whether it is an outreach from a U.S. transplant center or Organ Procurement Organization, our team is now able to rapidly deploy Paragonix devices to the site of organ donation 24/7/365.”
“The donation and transplant teams involved in donor organ procurements are working tirelessly around the clock to serve donor families and transplant recipients. While we have offered 24/7 clinical and technical support since market entry, we can now supercharge customer support with our OPTION program,” said Lisa Anderson, Ph.D., President & CEO at Paragonix Technologies, Inc. “This new offering will increase our coverage for any type of case that arises.”

OPTION is just the latest element in a strategy to provide advanced services to improve transplant efficiencies. Paragonix has already launched a digital platform to enhance transplant team coordination and data visibility. In future phases the company will be further expanding offerings to continue improve the efficiency and effectiveness of transplant services.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version